Mirati Therapeutics, Inc.

Form 3

March 21, 2014

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

À RINGO WILLIAM R

DRIVE, SUITE 200

(Last)

(First)

C/O MIRATI THERAPEUTICS,

INC., Â 9363 TOWNE CENTRE

(Street)

(Middle)

Statement

(Month/Day/Year)

03/19/2014

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Mirati Therapeutics, Inc. [MRTX]

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

(Check all applicable)

10% Owner \_X\_ Director Officer Other

(give title below) (specify below)

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

SAN DIEGO. CAÂ 92121

(City) (State)

1. Title of Security (Instr. 4)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial Ownership

(Instr. 5) Form: Direct (D) or Indirect

(I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

2. Date Exercisable and **Expiration Date** 

Date

3. Title and Amount of Securities Underlying **Derivative Security** 

5. 4 Conversion or Exercise Price of

6. Nature of Indirect Ownership Beneficial Ownership Form of (Instr. 5) Derivative

Derivative Security: Security Direct (D)

(Instr. 4)

(Month/Day/Year)

Exercisable

Date

(Instr. 4) **Expiration Title** 

Amount or Number of

Shares

or Indirect
(I)
(Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

RINGO WILLIAM R C/O MIRATI THERAPEUTICS, INC. 9363 TOWNE CENTRE DRIVE, SUITE 200 SAN DIEGO. CAÂ 92121

Â

Â

**Signatures** 

/s/ Jamie A. Donadio, Attorney-in-Fact

03/20/2014

ÂX

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Â

## **Remarks:**

No securities beneficially owned.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2